Hematological malignancy
Conditions
Interventions
Dose adjustment of cyclosporine by monitoring of its blood levels
Sponsors
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with hematological malignancies who undergo bone marrow transplantation from unrelated donors. 2) Donors need to be HLA-A, B, C, DRB1 genotypically matched, HLA-A, B, C genotypically matched and DRB1 single allele mismatched or HLA-A, B, DRB1 genotypically matched and HLA-C single allele mismatched and KIR matched. 3) Patients who can give written informed consent to the enrollment into this trial.
Exclusion criteria
Exclusion criteria: 1) Non-myeloablative allogeneic transplantation 2) Past transplantation history 3) T-cell depleted transplantation 4) Use of ATG or ALG as preparative regimens 5) Serum creatinine level >= 2.0 mg/dL or >= 1.5 times the upper limit of the normal range, Ccr < 50 mL/min 6) Serum total bilirubin level >= 2.0 mg/dL, serum AST/ALT level >= 2 times the upper limit of the normal range 7) Uncontrolled hypertension 8) Uncontrolled diabetes mellitus on insulin therapy 9) Uncontrolled active infections 10) History of epilepsy 11) Other severe complications 12) Pregnant female 13) Allergic to cyclosporine 14) Any patients who are judged unsuitable for the enrollment by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade II-IV and grade III-IV acute GVHD within 100 days after bone marrow transplantation. | — |
Countries
Japan
Contacts
Public ContactHirohito Yamazaki
Kanazawa University Graduate School of Medical Science Cellular Transplantation Biology
Outcome results
None listed